Diala Abd-Rabbo
YOU?
Author Swipe
View article: Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes
Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes Open
Type-II topoisomerases resolve topological stress in DNA through double-strand breaks. While topoisomerases are chemotherapy targets linked to therapy-related genotoxicity, TOP2B is uniquely positioned to influence mutagenesis through its …
View article: Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans
Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans Open
Glycans are emerging as important regulators of T cell function but remain poorly characterized across the functionally distinct populations that exist in vivo. Here, we couple single-cell analysis technologies with soluble lectins and che…
View article: Topoisomerase IIb binding underlies frequently mutated elements in cancer genomes
Topoisomerase IIb binding underlies frequently mutated elements in cancer genomes Open
Type-II topoisomerases resolve topological stress in DNA through controlled double-strand breaks. While TOP2A is a chemotherapy target in proliferating cells, the ubiquitously expressed TOP2B is a potential off-target. Here we explore role…
View article: A Unified Atlas of T cell Glycophysiology
A Unified Atlas of T cell Glycophysiology Open
SUMMARY Glycans are emerging as important regulators of T cell function but remain poorly characterized across the functionally distinct populations that exist in vivo . Here, we couple single-cell analysis technologies with soluble lectin…
View article: A Unified Atlas of T Cell Glycophysiology
A Unified Atlas of T Cell Glycophysiology Open
View article: Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control
Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control Open
View article: Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control
Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control Open
CD4 T cells are important effectors of anti-tumor immunity, yet the regulation of CD4 tumor-specific T (T TS ) cells during cancer development is still unclear. We demonstrate that CD4 T TS cells are initially primed in the tumor draining …
View article: Supplementary Table 3 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 3 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 99K, Common genes between our results and published inherited ovarian literature
View article: Supplementary Table 4 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 4 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 106K, Supplementary Table 4a. Oligonucleotides and Probes utilized for candidate genes quantification by q-RT-PCR Supplementary Table 4b. Oligonucleotides and Probes utilized for BRCA1 and BRCA2 quantification by q-RT-PCR
View article: Supplementary Table 2 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 2 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 123K, Review of inherited ovarian literature
View article: Supplementary Table 4 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 4 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 106K, Supplementary Table 4a. Oligonucleotides and Probes utilized for candidate genes quantification by q-RT-PCR Supplementary Table 4b. Oligonucleotides and Probes utilized for BRCA1 and BRCA2 quantification by q-RT-PCR
View article: Supplementary Table 1A-B from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1A-B from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 92K, Supplementary Table 1a. Molecular profile associated to a BRCA1 mutation in NOSEs Supplementary Table 1b. Molecular profile associated to a BRCA2 mutation in NOSEs
View article: Supplementary Table 1C from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1C from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 95K, Molecular profile differentiating BRCA1- from BRCA2-mutated NOSEs
View article: Data from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Data from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
We hypothesized that the transcriptome of primary cultures of morphologically normal ovarian surface epithelial cells could be altered by the presence of a heterozygous BRCA1 or BRCA2 mutation. We aimed to discover early even…
View article: Supplementary Table 1 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 65K, Summary of significant Limma Analysis Result for each of the candidate genes and contrast tested
View article: Supplementary Table 1D from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1D from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 177K, Molecular signature associated to the tumor transformation from NOSEs to TOVs in BRCA1-mutated samples
View article: Data from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Data from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
We hypothesized that the transcriptome of primary cultures of morphologically normal ovarian surface epithelial cells could be altered by the presence of a heterozygous BRCA1 or BRCA2 mutation. We aimed to discover early even…
View article: Supplementary Table 1D from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1D from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 177K, Molecular signature associated to the tumor transformation from NOSEs to TOVs in BRCA1-mutated samples
View article: Supplementary Table 1A-B from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1A-B from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 92K, Supplementary Table 1a. Molecular profile associated to a BRCA1 mutation in NOSEs Supplementary Table 1b. Molecular profile associated to a BRCA2 mutation in NOSEs
View article: Supplementary Table 1 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 65K, Summary of significant Limma Analysis Result for each of the candidate genes and contrast tested
View article: Supplementary Table 3 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 3 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 99K, Common genes between our results and published inherited ovarian literature
View article: Supplementary Table 2 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 2 from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 123K, Review of inherited ovarian literature
View article: Supplementary Table 1C from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation
Supplementary Table 1C from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i>/<i>2</i> French Canadian Founder Mutation Open
PDF file - 95K, Molecular profile differentiating BRCA1- from BRCA2-mutated NOSEs
View article: Author Correction: Integrative pathway enrichment analysis of multivariate omics data
Author Correction: Integrative pathway enrichment analysis of multivariate omics data Open
View article: Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection
Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection Open
View article: Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes
Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes Open
View article: The transcriptional landscape of Shh medulloblastoma
The transcriptional landscape of Shh medulloblastoma Open
View article: Additional file 2 of Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes
Additional file 2 of Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes Open
Additional file 2: Table S1A. Description of the open-chromatin sites of primary tumours and related normal tissues used in the analysis. Table S1B. Localised mutation frequencies in three classes of genomic sites across total mutations an…
View article: Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes
Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes Open
Background Cancer genomes are shaped by mutational processes with complex spatial variation at multiple scales. Entire classes of regulatory elements are affected by local variations in mutation frequency. However, the underlying mutationa…
View article: Integrative pathway enrichment analysis of multivariate omics data
Integrative pathway enrichment analysis of multivariate omics data Open